SCHEMBL2954098

SCHEMBL2954098

Fc1ccc(Oc2ccc3c(Cl)nncc3c2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR2 O95136 2/20 0.39
MAPK14 Q16539 3/20 0.38
GAA P10253 1/20 0.37
ABL1 P00519 1/20 0.37
SCN9A Q15858 7/20 0.36
PDE2A O00408 1/20 0.35
PDE10A Q9Y233 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
HTT P42858 1/20 0.35
MAPT P10636 1/20 0.34
KCNH2 Q12809 1/20 0.34
SCN5A Q14524 1/20 0.34
TRPA1 O75762 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29496596 0.82 C1S (0.38) MAPK14ABL1L3MBTL1MEN1KMT2A
SCHEMBL2949210 0.82 ABL1 (0.40) S1PR2MAPK14GAAABL1SCN9A
SCHEMBL2953194 0.79 MAPK14 (0.50) MAPK14SCN9APDE2APDE10AMAPT
SCHEMBL3373707 0.78 C1S (0.43) KMT2AMAPTCYP1A2CYP3A4CYP2C9
SCHEMBL2951647 0.76 MAPK14 (0.40) MAPK14GAAABL1SCN9AKCNH2
SCHEMBL599340 0.76 EGFR (0.49) MAPK14GAAMEN1KMT2AMAPT
SCHEMBL2948274 0.74 MAPK14 (0.54) MAPK14SCN9A
SCHEMBL2952776 0.74 MAPK14 (0.54) MAPK14ABL1SCN9A
SCHEMBL2951418 0.73 MAPK14 (0.68) MAPK14SCN9APDE2APDE10ACYP3A4
SCHEMBL2953635 0.73 PDGFRB (0.39) MAPK14GAAABL1SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1856058-B1 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2014-09-03 EP disclosed
US-7759337-B2 Phthalazine compounds and methods of use AMGEN INC. (US) 2010-07-20 US disclosed
EP-1856058-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-11-21 EP disclosed
WO-2006094187-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2006-09-08 WO disclosed
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use AMGEN INC. (US) 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use DAPK2, CDK2, DAPK1 S1PR2 1888/4885MAPK14 293/4885GAA 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.